<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215003</url>
  </required_header>
  <id_info>
    <org_study_id>SCHBCC0N026</org_study_id>
    <nct_id>NCT04215003</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC</brief_title>
  <official_title>This is a Phase Ib/II, Prospective , Open-label, Single Center, Bayesian Adaptive Design, Umbrella Study Evaluating the Efficacy and Safety of Neo-adjuvant Therapy in Patients With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design,
      umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with
      breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic Complete Response (pCR)</measure>
    <time_frame>3</time_frame>
    <description>pCR is defined as the absence of noninvasive tumor residuals in breast and axillary lymph nodes (ypT0/is ypN0) after neoadjuvant therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>3</time_frame>
    <description>ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CL1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR+ and HER2- without PI3K-AKT pathway mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CL2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR+ and HER2- with PI3K-AKT pathway mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLH1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR+ and HER2+ without PI3K-AKT pathway mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLH2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR+ and HER2+ with PI3K-AKT pathway mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CH1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR- and HER2+ without PI3K-AKT pathway mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CH2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR- and HER2+ with PI3K-AKT pathway mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patients were HR- and HER2- with LAR subtype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A</intervention_name>
    <description>Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.
Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B</intervention_name>
    <description>Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CL1</intervention_name>
    <description>Drug:
SHR6390（CDK4/6 inhibitor）150 mg qd(three week on one week off) Fulvestrant 500mg IM Q4W； Premenopause：Goserelin 3.6mg IM IM Q4W.</description>
    <arm_group_label>CL1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CL2</intervention_name>
    <description>Drug:
SHR6390（CDK4/6 inhibitor）150 mg qd(three week on one week off); Alpelisib 300mg PO QD； Premenopause：Goserelin 3.6mg IM IM Q4W.</description>
    <arm_group_label>CL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLH1</intervention_name>
    <description>Drug:
SHR6390（CDK4/6 inhibitor）150 mg qd(three week on one week off) Fulvestrant 500mg IM Q4W； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W.</description>
    <arm_group_label>CLH1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLH2</intervention_name>
    <description>Drug:
SHR6390（CDK4/6 inhibitor）150 mg qd (three week on one week off) Alpelisib 300mg PO QD； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W.</description>
    <arm_group_label>CLH2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CH1</intervention_name>
    <description>Drug:
pyrotinib(EGFR-TKI) 400mg qd； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； capecitabine 1000mg/m2 bid(d1-d14)</description>
    <arm_group_label>CH1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CH2</intervention_name>
    <description>Drug:
Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Alpelisib 300mg PO QD； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W.</description>
    <arm_group_label>CH2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT1</intervention_name>
    <description>Drug:
SHR6390（CDK4/6 inhibitor）150 mg po.qd(three week on one week off) SHR3680（AR inhibitor）240 mg po. qd.</description>
    <arm_group_label>CT1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70 years old Expected survival &gt; 12 months Baseline ECOG Performance Status
             rating 0-1 Naïve to chemotherapy or hormonal treatments Radiologically confirmed and
             biopsy diagnosed invasive ductal carcinoma of breast and prepared to be treated
             surgically Locally advance breast cancer of stage IIb-IIIc No concurrent malignancy
             (except controlled cervical carcinoma in situ or basal cell carcinoma of skin)
             Patients have measurable lesions (according to RECIST v1.1 criteria) Intention to
             cooperate with baseline puncture and neoadjuvant therapy No advanced metastasis or
             metastasis involving brain or liver Adequate bone marrow function, blood routine
             examination shows neutrophil count ≥ 1.5x109/L, hemoglobin level ≥ 100 g/L, Platelets
             ≥ 100 x 109/L Adequate liver and kidney function, serum aminotransferase (AST) ≤
             60U/L, serum total bilirubin ≤ 2.5 times ULN, serum creatinine ≤110μmol/L, urea
             nitrogen ≤7.1mmol/L No coagulation abnormality Normal heart function, with normal ECG
             and LVEF ≥ 55% Women of childbearing age agree to take reliable contraceptive measures
             during clinical trials, and negative serum or urine pregnancy test within 7 days prior
             to administration No coagulation abnormality Sign the informed consent statement and
             voluntarily receive follow-ups, treatments, laboratory tests and other research
             procedures according to protocol.

        Exclusion Criteria:

          -  Previous regional or systemic treatment for breast cancer (include but not limited to
             chemotherapy, radiotherapy, targeted therapy, other clinical trials) Inflammatory
             breast cancer, bilateral breast cancer or breast cancer already with distant
             metastasis Complicated with uncontrolled lung disease, severe infection, active peptic
             ulcer, blood clotting disorders, severe uncontrolled diabetes, connective tissue
             disorders or bone marrow suppression, and intolerance to neoadjuvant therapy or
             related treatment Peripheral neuropathy &gt;1 degree caused by any reason History of
             congestive heart failure, uncontrolled or symptomatic angina, arrhythmias or history
             of myocardial infarction, refractory hypertension (systolic blood pressure &gt; 180 mmHg
             or diastolic blood pressure &gt; 100 mmHg); Breast cancer during lactation or pregnancy
             Unwillingly to receive baseline puncture or neoadjuvant therapy Mental illness or
             incompliance to treatment caused by other reasons Known history of severe
             hypersusceptibility to any agents used in the treatment protocol Patients received
             major surgery or suffered from severe trauma within 2 months of first administration
             Currently enroll or recently used (30 days within enrollment) other agent under
             research or involved in other trial Known to be infected with human immunodeficiency
             virus (HIV) Other circumstances considered to be inappropriate to be enrolled by
             researchers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhimin Shao, MD.PhD.</last_name>
    <phone>18017312288</phone>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Precision neo-adjuvant therapy of Breast Cancer Based on Molecular pathway</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neo-adjuvant therapy</keyword>
  <keyword>molecular pathway</keyword>
  <keyword>umbrella trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

